causal
Tech transfer is a bigger biotech bottleneck
The main barrier to commercializing research from institutions is not the technology itself but the opaque technology-transfer process, which is a structural inhibitor that must be solved to speed up innovation.
causalpending
Speaker
Daniel EkEvidence Quote
“there are also a lot of structural inhibitors, maybe more so than the technology in itself, that makes some of that not happening”
Source
Daniel Ek - Enabling Creators Everywhere - [Invest Like the Best, EP. 242]— Invest Like the BestCreated: 11/12/2026, 12:38:10 AM
Your notes
Loading notes...